Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can Blood-Type-Matched platelets make transfusions safer?

NCT ID NCT06613425

Symptom relief Sponsor: The General Hospital of Western Theater Command Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 11, 2026 · Last updated Sep 11, 2026

Summary

Researchers are testing a new way to prepare platelets for transfusion that matches a patient's ABO blood type. The study enrolls adults aged 18 to 65 who need platelet transfusions for blood disorders. Doctors measure platelet counts and bleeding before and after transfusion to see if the combined platelets work as well as standard platelets, and they track any side effects.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
combined platelets, a blood product made to match ABO blood type
What this could lead to
If it works, hospitals could have an easier way to give platelet transfusions that match a patient's blood type, which may lower the chance of reactions and make transfusions more reliable.
What could go wrong
This is a single-arm study, meaning everyone receives the same treatment and there is no comparison group, so it cannot prove the approach is better than standard care. Platelet transfusions carry risks of allergic reactions, fever, and other complications, and the results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

266 people

The number who actually took part.

Started

Aug 2024

Finished

Mar 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 1\. Aged 18-65 years; 2. Disease treatment in the research hospital; 3. Applied for platelet transfusion therapy. Exclusion Criteria: * 1\. One month before the start of this study, he participated in other clinical trials of drugs and instruments related to platelet transfusion efficacy; 2. Without platelet transfusion indications; 3. Only received platelet transfusion in the outpatient department and left the hospital without efficacy evaluation after transfusion; 4. Gave up platelet transfusion therapy for any reason after enrollment; 5. Transferred or discharged from hospital for any reason before platelet transfusion after enrollment; 6. Did not receive combined platelet transfusion during the 6-month treatment period after enrollment

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hematologic diseases are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hematologic disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hematologic diseases

Contacts and locations

Locations

  • Li Zhang

    Chengdu, Sichuan, 610083, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.